scholarly journals Linked Patient-Reported Outcomes Data From Patients With Multiple Sclerosis Recruited on an Open Internet Platform to Health Care Claims Databases Identifies a Representative Population for Real-Life Data Analysis in Multiple Sclerosis

2016 ◽  
Vol 18 (9) ◽  
pp. e249 ◽  
Author(s):  
Valery Risson ◽  
Bhaskar Ghodge ◽  
Ian C Bonzani ◽  
Jonathan R Korn ◽  
Jennie Medin ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Health Care ◽  
Data Analysis ◽  
Patient Reported Outcomes ◽  
Real Life ◽  
Life Data ◽  
Real Life Data ◽  
Patient Reported ◽  
Internet Platform ◽  
Health Care Claims

Assessing the performances of a chatbot to collect real-life data of patients with migraine (Preprint)

2020 ◽  
Author(s):  
Benjamin Chaix ◽  
Jean-Emmanuel Bibault ◽  
Guillaume Delamon ◽  
Mickaël Neraal ◽  
Julien Moussalli ◽  
...  
Keyword(s):  
Patient Reported Outcomes ◽  
Real Life ◽  
Text Messages ◽  
Remote Diagnosis ◽  
Medical Assessment ◽  
Life Data ◽  
Real Life Data ◽  
Patient Reported ◽  
The Impact ◽  
Assessment Scales

BACKGROUND There are many scales for screening or assessing the impact of a disease. These scales are generally used to diagnose or assess the severity of a disease and are carried out by doctors. The Vik Migraine chatbot helps patients suffering from headaches through personalized text messages, it could be used to collect patient-reported outcomes. OBJECTIVE The aims of this study were (1) to assess the feasibility of collecting a chatbot-mediated reference scale, (2) perform a remote diagnosis of the severity of the migraines and (3) assess the patient satisfaction and engagement with the chatbot. METHODS This study was conducted in France from December 2019 to March 2020. Voluntary users of the chatbot Vik Migraine were recruited online. They had to be adults and suffer from chronic migraines. An adapted version of the IHS questionnaire was presented to the participants by text messages. The Lickert scale ranging from 1 to 5 was used to assess overall satisfaction with the use of Vik Migraine. RESULTS We included 636 participants with migraines or headaches. A total of 89.94% (572) participants had fully completed the IHS questionnaire (8 items), 4.72% (30) had partially completed it and 5.35% (34) had refused to complete it. The evaluation of overall satisfaction shows that a total of 80.7% (513) of users agreed or strongly agreed with the affirmation that Vik Migraine provides quality answers about the pathology or its information. CONCLUSIONS We hypothesized that a virtual assistant built to support migraine patients could be used to retrieve patient data remotely, such as medical assessment scales. The study confirmed this hypothesis and showed that users were strongly engaged through to chatbot: out of the total number of participants, we observed a very low number of uncompleted questionnaires.

scholarly journals Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry

2019 ◽  
Vol 266 (11) ◽  
pp. 2678-2678
Author(s):  
Michael Guger ◽  
◽  
Christian Enzinger ◽  
Fritz Leutmezer ◽  
Jörg Kraus ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

P.3.d.031 Antipsychotic treatment in schizophrenia and related psychosis, real life data analysis of oral and long acting antipsychotics

2015 ◽  
Vol 25 ◽  
pp. S496
Author(s):  
M. Eftekhari ◽  
A. Berntsson ◽  
S. Svensson ◽  
J. Hjortsberg ◽  
E. Jedenius ◽  
...  
Keyword(s):  
Data Analysis ◽  
Real Life ◽  
Antipsychotic Treatment ◽  
Life Data ◽  
Real Life Data ◽  
Long Acting

Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry

2019 ◽  
Vol 266 (11) ◽  
pp. 2672-2677 ◽  
Author(s):  
Michael Guger ◽  
◽  
Christian Enzinger ◽  
Fritz Leutmezer ◽  
Jörg Kraus ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

scholarly journals Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

2021 ◽  
Author(s):  
Michael Guger ◽  
◽  
Christian Enzinger ◽  
Fritz Leutmezer ◽  
Franziska Di Pauli ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Rate Ratio ◽  
Disease Duration ◽  
Treatment Initiation ◽  
Incidence Rate Ratio ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

Abstract Objectives To evaluate long-term effectiveness of natalizumab (NTZ) and to determine demographic, clinical, and radiological predictors regarding long-term disease activity (≥ 7 years) in a nationwide observational cohort, using data collected prospectively in a real-life setting. Materials and methods We analysed data from 230 patients from the Austrian Multiple Sclerosis Treatment Registry (AMSTR), who had started treatment with NTZ at any time since 2006 and stayed on NTZ for at least 7 years without treatment gap of more than three months. Results Estimated mean annualised relapse rates (ARR) over a mean treatment period of 9.3 years were 0.07 for NTZ. Sustained EDSS progression for 12 weeks was observed in 36 (19%) patients and for 24 weeks in 31 (16.3%) cases. Sustained EDSS regression for 12 and 24 weeks was seen in 45 (23.7%) and 42 (22.1%) cases. The baseline parameters ≥ 1 Gadolinium-enhancing MRI lesion(s) [incidence rate ratio (IRR) of 0.409 (95% CI 0.283–0.593), p = 0.001], ARR ≤ 1 in the prior 12 month before treatment initiation with NTZ [IRR of 0.353 (95% CI 0.200–0.623), p = 0.001] and EDSS ≤ 1 [incidence rate ratio (IRR) of 0.081 (95% CI 0.011–0.581), p = 0.012] were significantly associated with a reduced relapse risk, whereas a disease duration ≤ 5 years increased significantly the ARR [IRR of 1.851 (95% CI 1.249–2.743), p = 0.002]. The only predictive baseline parameter for experiencing EDSS progression (sustained for 12 and 24 weeks) was age > 35 years [HR of 2.482 (95% CI 1.110–5.549), p = 0.027, and HR of 2.492 (95% CI 1.039–5.978), p = 0.041, respectively]. Conclusions These real-life data show a stable disease course regarding relapse activity and disease progression under NTZ treatment for more than 7 years. The main predictors for disease activity were higher relapse rate before treatment initiation, higher disability, shorter disease duration and absence of Gadolinium-enhancing MRI lesions at baseline. Older age at NTZ start was the only significant risk factor for disease progression over long-term.

Sign in / Sign up

Export Citation Format

Share Document